Shares of Chemours (CC) tumbled 5.87% on Tuesday following the release of the company's first-quarter 2025 earnings report, which presented a mixed picture of its financial performance and included several disappointing announcements for investors.
The chemical company reported adjusted earnings per share (EPS) of $0.13, significantly below the analyst consensus estimate of $0.21. This represents a 59.38% decrease compared to the same period last year. Despite the earnings miss, Chemours managed to outperform on the top line, reporting Q1 sales of $1.4 billion, surpassing the analyst estimate of $1.352 billion. However, the company's adjusted EBITDA of $166 million fell short of the expected $171.3 million.
Adding to investor concerns, Chemours lowered the top end of its full-year adjusted EBITDA guidance to between $825 million and $950 million, down from the previous range of $825 million to $975 million. The company also announced a drastic 65% reduction in its quarterly dividend to $0.0875 per share, citing the need to better align its capital allocation and achieve balance sheet flexibility. These factors, combined with the earnings miss, appear to be the primary drivers behind the stock's sharp decline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.